TriSalus Life Sciences, Inc. (TLSIW)
| Market Cap | 141.60M -23.1% |
| Revenue (ttm) | 46.39M +39.6% |
| Net Income | -26.26M |
| EPS | -0.49 |
| Shares Out | 61.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50 |
| Open | 0.9400 |
| Previous Close | n/a |
| Day's Range | 0.9400 - 0.9400 |
| 52-Week Range | 0.4405 - 1.8500 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 10, 2026 |
About TLSIW
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device... [Read more]
News
TriSalus Life Sciences to Participate in the 38th Annual Piper Sandler Healthcare Conference on December 1, 2026
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel medicine delivery technology with standard of care therapies t...
TriSalus Life Sciences Transcript: Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Revenue guidance fell to $46M-$48M as new territories ramped more slowly, while management cited maturing reps, TriNav Advance and reimbursement as 2027 growth drivers. December pipeline data and improved EBITDA loss are key near-term milestones.
TriSalus Life Sciences price target lowered to $6 from $8 at Lake Street
Lake Street analyst Frank Takkinen lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $6 from $8 and keeps a Buy rating on the shares. The firm lowered…
TriSalus Life Sciences price target lowered to $4 from $7 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $4 from $7 and keeps a Buy rating on the shares. The firm said the…
TriSalus Life Sciences price target lowered to $10 from $12 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $10 from $12 and keeps a Buy rating on the shares following the Q3 miss. The company’s…
TriSalus Life Sciences reports Q3 EPS (15c) vs (96c) last year
Reports Q3 revenue $12.878M, consensus $14.02M. “The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-over-year growth and received FDA cleara...
TriSalus Life Sciences sees FY26 revenue $46M-$48M, consensus $53.12M
The Company is updating its full-year 2026 revenue guidance to $46M-$48M, representing growth of approximately 2% to 6% compared to full year 2025.
TriSalus Life Sciences Earnings Call Transcript: Q3 2026
Q3 revenue rose 11% YoY, but slower new-territory ramping constrained growth and FY2026 guidance was reduced to $46M-$48M. FDA clearance for TriNav Advance and improved 2027 reimbursement underpin management’s growth outlook.
TriSalus Life Sciences Earnings release: Q3 2026
TriSalus Life Sciences released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
TriSalus Life Sciences Quarterly report: Q3 2026
TriSalus Life Sciences has published its Q3 2026 quarterly earnings report on November 10, 2026.
TriSalus Life Sciences Reports Third Quarter 2026 Results
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...
TriSalus Life Sciences Slides: Investor presentation
TriSalus Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapie...
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an inves...
TriSalus Life Sciences price target raised to $12 from $11 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on TriSalus Life Sciences (TLSI) to $12 from $11 and keeps a Buy rating on the shares. Following TriNav Advance clearance, the firm…
TriSalus Life Sciences receives FDA clearance for TriNav Advance
TriSalus Life Sciences (TLSI) announced it has received U.S. Food and Drug Administration 510(k) clearance for TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery portfolio. TriN...
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its inve...
TriSalus Life Sciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is driving innovation in solid tumor therapy with a unique catheter technology, expanding its sales force, and targeting new clinical indications. Strong revenue growth, improving margins, and a robust cash position support its outlook, with key catalysts including new product launches and broader market access.
TriSalus Life Sciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of TriSalus Life Sciences (TLSI) with a Buy rating and $11 price target TriSalus is a commercial-stage device with an FDA-cleared TriN...
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference.
TriSalus Life Sciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
A smart valve catheter technology is driving improved drug delivery and outcomes in solid tumors, with imminent FDA clearance for TriNav ADVANCE expected to expand the addressable market by 20%. Strong clinical evidence, new reimbursement codes, and a scaled sales force position the company for significant near-term growth.
TriSalus Life Sciences reports Q2 EPS (16c), consensus (16c)
Reports Q2 revenue $11.4M, consensus $10.27M. “We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our foundation to drive future expansion ...
TriSalus Life Sciences sees FY26 revenue $54M-$57M, consensus $52.4M
The Company is maintaining its full-year 2026 revenue guidance of $54M-$57M, consistent with the range set in the first quarter and representing growth of 19% to 26% compared to full…
TriSalus Life Sciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew to $11.4M, driven by TriNav demand and commercial expansion. CMS approved a G-code for OBL reimbursement, broadening market access. Full-year revenue guidance of $54–$57M was reiterated, with sequential growth and cost discipline expected.
TriSalus Life Sciences Earnings release: Q2 2026
TriSalus Life Sciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.